Lymphoma Hub

Lymphoma Hub

The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

Hosted on Acast. See acast.com/privacy for more information.

Den här podcasten är hämtad från ett öppet RSS-flöde och publiceras inte av Podme. Den kan innehålla reklam.

Avsnitt(53)

SEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL

SEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL

During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub was pleased to speak to Paolo Ghia, Vita-Salute San Raffaele, Milan, IT. We asked about the latest updates from ...

12 Aug 20244min

SYMPHONY 1: A trial update

SYMPHONY 1: A trial update

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked for an updat...

9 Jan 20235min

Novel therapies in chronic lymphocytic leukemia: An update.

Novel therapies in chronic lymphocytic leukemia: An update.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Chan Cheah, University of Western Australia, Perth, AU. We asked for an update on novel th...

5 Jan 20238min

What are the CAR T-cell therapies on the horizon for lymphoma?

What are the CAR T-cell therapies on the horizon for lymphoma?

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Pere Barba, Hospital Universitari Vall d'Hebron, Barcelona, ES. We asked, What are the chi...

3 Jan 20234min

How do you choose among different BTK inhibitors for treating CLL?

How do you choose among different BTK inhibitors for treating CLL?

The Lymphoma Hub was pleased to speak with Francesc Bosch, Vall d’Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, How do you choose among different BTK inhibitors for treating CLL?Bosch ope...

2 Dec 20227min

What are the latest advances in basal PET/CT for Hodgkin and non-Hodgkin lymphoma?

What are the latest advances in basal PET/CT for Hodgkin and non-Hodgkin lymphoma?

The Lymphoma Hub was pleased to speak with Astrid Pavlovsky, FUNDALEU, Buenos Aires, AR. We asked, What are the latest advances in basal PET/CT for Hodgkin and non-Hodgkin lymphoma?Pavlovsky outlines ...

7 Nov 20229min

ASCT in DLBCL – is it over?

ASCT in DLBCL – is it over?

As part of our biannual steering committee meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, USA, chaired a discussion session on the current and future role of autologous stem...

3 Aug 202217min

What is on the horizon for the frontline treatment of MCL?

What is on the horizon for the frontline treatment of MCL?

During the ASCO2022 congress, the Lymphoma Hub was pleased to speak with Anita Kumar, Memorial Sloane Kettering Cancer Center, New York, US. We asked, What is on the horizon for the frontline treatmen...

25 Juli 20227min

Populärt inom Utbildning

historiepodden-se
det-skaver
rss-bara-en-till-om-beroende-medberoende
nu-blir-det-historia
allt-du-velat-veta
harrisons-dramatiska-historia
not-fanny-anymore
rss-viktmedicinpodden
roda-vita-rosen
johannes-hansen-podcast
rikatillsammans-om-privatekonomi-rikedom-i-livet
sa-in-i-sjalen
i-vantan-pa-katastrofen
rss-max-tant-med-max-villman
sektledare
rss-ar-det-rimligt
rss-basta-livet
rss-foraldramotet-bring-lagercrantz
sex-pa-riktigt-med-marika-smith
rss-sjalsligt-avkladd